-
Fluoxetine HCl: Serotonin, Plasticity, and Motivation
2026-09-01
Fluoxetine HCl is a selective serotonin reuptake inhibitor that blocks serotonin transport and supports mechanistic studies of serotonergic signaling. Its receptor, neurogenesis, and developmental-exposure findings must be interpreted as assay-specific evidence rather than proof of a uniform behavioral or therapeutic effect.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-08-31
The reference study reports that thymoquinone protects mice from doxorubicin-associated cardiac injury, linking improved cardiac function with Nrf2/HO-1 activation, antioxidant restoration, mitochondrial preservation, and reduced ferroptosis-related changes. Its main practical value is the integration of physiological, biochemical, molecular, histological, and ultrastructural endpoints in a preclinical cardiotoxicity workflow.
-
U 46619: Platelet and Vascular Research Workflows
2026-08-30
U 46619 converts TP-receptor biology into measurable platelet, vascular, renal, and blood-pressure phenotypes. This practical guide organizes concentration selection, timing, controls, and troubleshooting around its distinct early and late response windows.
-
AZD1390: Selective ATM Kinase Inhibitor
2026-08-29
AZD1390 is a selective ATM kinase inhibitor with a reported cellular IC50 of 0.78 nM. Product data support its use as a radiosensitizer for glioma and lung cancer research, while the G4 replication study provides a separate mechanistic context for ATM and ATR signaling during replication stress.
-
Marein Reverses Mitoxantrone Resistance via ABCG2
2026-08-28
The reference study identifies marein, a chalcone glucoside from Coreopsis tinctoria, as a competitive inhibitor of ABCG2-mediated drug efflux. By increasing intracellular concentrations of ABCG2 substrates, including Mitoxantrone, marein restored chemotherapy sensitivity in resistant cancer-cell models and linked this activity to interaction with the conserved F439 residue.
-
YM 58483 (BTP2) for SOCE Workflows
2026-08-28
YM 58483 (BTP2) provides a practical way to suppress sustained store-operated calcium entry while connecting calcium flux to NFAT, IL-2, and fibrotic signaling readouts. This guide adapts the compound for T cell activation assays and radiation-induced salivary-gland fibrosis models, with executable setup parameters and troubleshooting controls.
-
KU-60019: ATM Kinase Inhibitor Workflow
2026-08-27
KU-60019 is a potent, selective ATM kinase inhibitor for connecting DNA damage response experiments with glioma radiosensitization, migration assays, and metabolic vulnerability studies. This workflow-focused guide explains how to prepare, benchmark, combine, and troubleshoot the compound while keeping ovarian cancer findings appropriately hypothesis-generating.
-
BPN-19186 in sEH–Nrf2 Research Workflows
2026-08-27
BPN-19186 supports concentration-controlled studies of sEH-linked metabolite balance, Nrf2 signaling, and osteoclast differentiation. This guide translates a recent liver–bone-axis finding into practical biochemical, cellular, and troubleshooting workflows without overstating product-specific efficacy.
-
Fenipentol: Applied Workflows for Secretory Biology
2026-08-26
Fenipentol, also called 1-Phenyl-1-pentanol, supports practical investigations of hepatobiliary secretion, ESR1-linked signaling, and gastrointestinal physiology. This guide separates compound-specific evidence from findings on the related isomer 1-phenyl-2-pentanol, helping researchers design cleaner assays and avoid overinterpreting cross-compound results.
-
ABT-263 (Navitoclax) in Apoptosis Assays
2026-08-26
This scenario-driven guide explains how ABT-263 (Navitoclax), SKU A3007, can improve the design, handling, and interpretation of apoptosis and cell-viability experiments. It connects Bcl-2 family pharmacology with practical stock-preparation, assay-compatibility, resistance-analysis, and vendor-selection decisions.
-
GluN2A/GluN2B Control of TMJ Inflammatory Allodynia
2026-08-25
This reference study identifies a mechanistic link between trigeminal ganglion NMDAR subunits GluN2A and GluN2B and connexin- or pannexin-dependent communication during temporomandibular joint inflammation. Conditional knockout and satellite glial cell experiments indicate that the two subunits have distinct effects on peripheral sensitization, providing a framework for testing pathway-selective interventions in orofacial pain.
-
IR-820 (New Indocyanine Green) in Cell Assays
2026-08-25
Learn how IR-820 (New Indocyanine Green), SKU C8228, can support near-infrared imaging controls without being mistaken for a direct viability reagent. This scenario-based guide covers spectral interference, protocol design, data interpretation, storage, and practical vendor-selection criteria.
-
FITC Goat Anti-Mouse IgG: Assay Design Guide
2026-08-24
Learn how the FITC Goat Anti-Mouse IgG (H+L) Antibody supports rigorous mouse IgG detection in microscopy and flow cytometry. This guide connects secondary-antibody design with multi-omics-informed ovarian aging research and practical assay controls.
-
Triazole ALDH2 Activators in Myocardial Ischemia
2026-08-24
A 2025 ACS Medicinal Chemistry Letters study used molecular simulation and structure optimization to develop triazole-based ALDH2 activators with improved activity and water solubility. Lead compound Z17 showed strong enzyme activation and protected cardiac function in a mouse ischemia–reperfusion model, supporting further preclinical investigation while leaving pharmacokinetic and clinical questions unresolved.
-
Separating Drug Growth Inhibition from Cell Death
2026-08-23
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug studies. Its central contribution is a response-analysis framework that separates proliferative arrest from actual cell killing, improving interpretation of drug timing, potency, and mechanism.